TY - JOUR
T1 - Molecular imaging of prostate cancer
AU - Boustani, Anne Marie
AU - Pucar, Darko
AU - Saperstein, Lawrence
N1 - Publisher Copyright:
© 2018 British Institute of Radiology. All rights reserved.
PY - 2018
Y1 - 2018
N2 - Prostate cancer is a common malignancy with various treatments from surveillance, surgery, radiation and chemotherapy. The institution of appropriate, effective treatment relies in part on accurate imaging. Molecular imaging techniques offer an opportunity for increased timely detection of prostate cancer, its recurrence, as well as metastatic disease. Advancements within the field of molecular imaging have been complex with some agents targeting receptors and others acting as metabolic intermediaries. In this article, we provide an overview of the most clinically relevant radiotracers to date based on a combination of the five States model and the National Comprehensive Cancer Network Guidelines.
AB - Prostate cancer is a common malignancy with various treatments from surveillance, surgery, radiation and chemotherapy. The institution of appropriate, effective treatment relies in part on accurate imaging. Molecular imaging techniques offer an opportunity for increased timely detection of prostate cancer, its recurrence, as well as metastatic disease. Advancements within the field of molecular imaging have been complex with some agents targeting receptors and others acting as metabolic intermediaries. In this article, we provide an overview of the most clinically relevant radiotracers to date based on a combination of the five States model and the National Comprehensive Cancer Network Guidelines.
UR - http://www.scopus.com/inward/record.url?scp=85044692114&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85044692114&partnerID=8YFLogxK
U2 - 10.1259/bjr.20170736
DO - 10.1259/bjr.20170736
M3 - Review article
C2 - 29243485
AN - SCOPUS:85044692114
SN - 0007-1285
VL - 91
JO - British Journal of Radiology
JF - British Journal of Radiology
IS - 1084
M1 - 20170736
ER -